

## Influenza B Victoria lineage egg-derived<sup>1</sup> candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)<sup>2</sup>

**27 February 2026 (Last updated 12 March 2026)**

### Candidate vaccine viruses antigenically like B/Tokyo/EIS13-175/2025 (egg derived) - Accession number (GISAID): EPI\_ISL\_20373028

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Tokyo/EIS13-175/2025		Wild type	NIID, Japan	NIID, Japan CCDC, China
B/Tokyo/EIS13-011/2025		Wild type	NIID, Japan	NIID, Japan CCDC, China
<a href="#">B/Perth/115/2025*</a>		Wild type	VIDRL, Australia	NIID, Japan VIDRL, Australia

*\*New CVV shown in blue*

#### Institutes contact details for candidate vaccine virus orders/information:

CCDC: [fluchina@ivdc.chinacdc.cn](mailto:fluchina@ivdc.chinacdc.cn)

NIID: [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

VIDRL: [enquiries@influenzacentre.org](mailto:enquiries@influenzacentre.org)

WHO CCs: [http://www.who.int/influenza/gisrs\\_laboratory/collaborating\\_centres/list/en/](http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/)

<sup>1</sup> For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

<sup>2</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze-dried) – to be updated

Parent virus	Starting materials		Ref Ag	Unitage	Available from
	Candidate vaccine virus	Egg or cell	Lot number	( $\mu$ g HA/ml)	

## Sheep antisera – to be updated

Purified HA from		Order	Available from
Parent virus	Egg or Cell	Lot number	

The above-listed potency testing reagents have been developed with support from manufacturers and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

### WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**NIID:** [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

**TGA:** [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from **CBER**, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov)

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)